Medulloblastoma is a highly malignant paediatric brain tumour currently treated with a combination of surgery, radiation and chemotherapy, posing a considerable burden of toxicity to the developing child. Genomics has illuminated the extensive intertumoral heterogeneity of medulloblastoma, identifying four distinct molecular subgroups. Group 3 and group 4 subgroup medulloblastomas account for most paediatric cases; yet, oncogenic drivers for these subtypes remain largely unidentified. Here we describe a series of prevalent, highly disparate genomic structural variants, restricted to groups 3 and 4, resulting in specific and mutually exclusive activation of the growth factor independent 1 family protooncogenes, GFI1 and GFI1B. Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity. Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate 'enhancer hijacking' as an efficient mechanism driving oncogene activation in a childhood cancer.
Medulloblastoma is a highly malignant paediatric brain tumour currently treated with a combination of surgery, radiation and chemotherapy, posing a considerable burden of toxicity to the developing child. Genomics has illuminated the extensive intertumoral heterogeneity of medulloblastoma, identifying four distinct molecular subgroups. Group 3 and group 4 subgroup medulloblastomas account for most paediatric cases; yet, oncogenic drivers for these subtypes remain largely unidentified. Here we describe a series of prevalent, highly disparate genomic structural variants, restricted to groups 3 and 4, resulting in specific and mutually exclusive activation of the growth factor independent 1 family protooncogenes, GFI1 and GFI1B. Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity. Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate 'enhancer hijacking' as an efficient mechanism driving oncogene activation in a childhood cancer.
Recent genome sequencing studies of medulloblastoma, a leading cause of cancer-related mortality in children 1 , have yielded considerable insight into the genes, pathways and overall mutational landscape contributing to its pathogenesis [2] [3] [4] . Despite these advances, medulloblastoma remains a vastly heterogeneous disease characterized by very few recurrently mutated genes 5 . Medulloblastoma comprises at least four distinct molecular subgroups-wingless (WNT), sonic hedgehog (SHH), group 3 and group 4-each of which exhibits unique clinical and biological attributes, consistent with the concept of medulloblastoma existing not as a single entity, but more aptly a collection of different diseases 6, 7 . Of the consensus subgroups, group 3 and 4 medulloblastomas have the poorest outcomes and remain least understood in terms of underlying genetics and biology 5 . Somatic MYC and MYCN amplifications rank among the most prevalent driver events known in these subgroups, altered in just 17% (MYC) and 6% (MYCN) of group 3 and group 4 medulloblastomas, respectively 8 . Recurrent, somatically mutated genes are equally scarce, and for most cases, no obvious somatic 'drivers' have yet been revealed 5 . By analysing medulloblastoma genome sequencing data from different initiatives 2, 4 , we identified a series of spatially clustered somatic genomic structural variants (SVs) involving diverse SV classes that are linked to activation of GFI1B or its paralogue GFI1 in group 3 and group 4 medulloblastomas. Further genomic and epigenomic analyses revealed a varied yet consistent interplay between SVs and the underlying epigenome that can explain GFI1 and GFI1B activation in most cases. Functional analyses performed in mice confirmed the oncogenicity of GFI1 and GFI1B in the context of medulloblastoma. Collectively, these studies establish GFI1 and GFI1B as novel, highly prevalent medulloblastoma oncogenes specifically activated in group 3 and group 4.
Diverse SVs activate GFI1B in medulloblastoma
Whole-genome sequencing (WGS; standard 100-base-pair (bp), pairedend and large-insert paired-end sequencing, see Methods) of 137 primary group 3 and 4 medulloblastoma samples (46 published 2, 4 and 91 newly generated; Supplementary Table 1 ) facilitated a systematic, highresolution screen for somatic SVs targeting novel medulloblastoma drivers. Rather than limiting our search to minimal common regions of recurrent amplification or deletion, a well-established approach for identifying somatically altered cancer genes 9, 10 , we considered all chromosomal rearrangements (that is, breakpoint clusters) detectable by WGS, including deletions, insertions, tandem duplications, amplifications, inversions and complex variants involving different SV classes (see Methods). Loci harbouring known medulloblastoma-related genes, including MYCN (2p24.3), MYC (8q24.21) and SNCAIP (5q23.2) 8 , were readily recovered using this strategy (Fig. 1a) . A novel prominent region of 
ARTICLE RESEARCH
interest mapped to chromosome 9q34.13 (Fig. 1a) . Further assessment of our entire discovery series identified 9 of 137 (6.6%) cases with evidence of focal SV spanning this region of interest on chromosome 9 (135.46-135.89 megabases (Mb), ,425 kilobases (kb); Fig. 1b) . Instead of showing a predilection for a particular SV type, we observed a range of different SV classes at 9q34, including focal deletion (n 5 4), tandem duplication (n 5 3), and complex variants exhibiting inversions and focal deletions (n 5 2). Examination of microarray-based copy-number data from our recent medulloblastoma genomics study 8 revealed additional evidence for subgroup-specific incidence of recurrent SVs affecting this region (Extended Data Fig. 1) .
The region of interest on 9q34 harbours seven known genes (Fig. 1b) , including the TSC1 tumour suppressor gene previously implicated in medulloblastoma 11 . Integration of SV status with sample-matched gene expression data, however, uncovered highly specific transcriptional upregulation of GFI1B in samples harbouring 9q34 SV compared to nonaffected counterparts (P , 0.00001, Fig. 1c ). In contrast, neither TSC1 nor any of the other remaining candidate genes exhibited a significant difference in expression in this context (Fig. 1c) . Analysis of GFI1B expression in a large series of medulloblastomas (n 5 727) 4, 8 further substantiated this candidate, confirming restriction of GFI1B activation to groups 3 and 4, affecting 10.7% and 3.5% of cases from these subgroups, respectively (Fig. 1d) .
To further characterize the relationship between somatic SVs at 9q34 and GFI1B transcriptional activation, we sequenced a validation set of 11 group 3 and group 4 medulloblastomas exhibiting GFI1B expression, confirming the existence of somatic SVs in 10 of 11 cases (Supplementary Table 2 ). In just one case (MAGIC_MB179), we failed to detect an underlying SV, suggesting that GFI1B overexpression might, in rare instances, be driven by an alternative non-SV-associated mechanism. Collectively, among 119 group 3 and group 4 medulloblastomas for which both WGS and matched expression array data were available, 16 of 18 (89%) GFI1B-activated cases displayed a detectable underlying SV (Fig. 1e) .
Importantly, every case showing SV at the 9q34 locus was associated with accompanying activation of GFI1B expression.
We next investigated each of the somatic SVs occurring at this locus in further detail to determine the mechanisms of GFI1B activation. Interestingly, irrespective of the underlying SV class, in 14 of 18 unique cases these events repositioned GFI1B proximal to the terminal sequence of the DDX31 gene, a region that is normally positioned ,370 kb upstream of the GFI1B transcriptional start site (TSS) (Fig. 2a and Supplementary Table 2 ). Most affected samples annotated in our series juxtapose GFI1B within ,40 kb of DDX31, with the most distal introns of DDX31 positioned either upstream or downstream of GFI1B, depending on the individual SV. Additionally, a smaller subset of examined cases (4 of 18) was found to exhibit broader deletions (,1.6 Mb) and complex rearrangements spanning a consistent region that starts upstream of the PRRC2B gene (chromosome 9, 134.27-134.28 Mb) and extends into the first intron (upstream of the first coding exon) of GFI1B (Fig. 2b) .
The pattern of observed SVs does not support fusions of the DDX31 coding sequence or its promoter with GFI1B as a common means of gene activation (see Fig. 2a ). DDX31-GFI1B fusion transcripts were detected in two cases (2 of 4 GFI1B-activated medulloblastomas with available RNA-seq data: ICGC_MB9 and ICGC_MB247) but these were predicted to constitute non-functional (antisense or out-of-frame) alternative transcripts, not resulting in GFI1B activation (Extended Data Fig. 2 ).
Active enhancers drive GFI1B expression
The unexpected yet consistent observation of SVs resulting in juxtaposition of GFI1B to DNA elements normally located several hundred kilobases upstream suggested that rearrangements of cis-acting regulatory elements (such as enhancers) within these regions might be responsible for GFI1B activation. DDX31 is highly expressed in group 3 and group 4 medulloblastomas and shows a correlated expression pattern with its two closest neighbours, BARHL1 (downstream) and GTF3C4 (upstream), suggesting that this locus exists in a transcriptionally permissive chromatin state in these medulloblastoma subgroups (Extended Data  Fig. 3 ). To examine this locus and the surrounding region for evidence of enhancer activity, we used chromatin immunoprecipitation coupled with sequencing (ChIP-seq) for H3K27ac and H3K9ac, both known to mark active enhancers 12 , in six primary group 3 medulloblastomas (Supplementary Table 1 ), including three GFI1B-activated cases (MAGIC_ MB399, MAGIC_MB360 and ICGC_MB9; marked with an asterisk; Fig. 3a ). Peak identification of these histone modification data predicted the presence of multiple enhancer clusters in this region, with peak H3K27ac and H3K9ac signals prominently overlapping or found immediately adjacent to the SV breakpoints observed in GFI1B-activated cases (Fig. 3a) . Such clustering of highly active enhancers, and the overall H3K27 acetylation signal measured for these regions, is consistent with the recently described super-enhancers-regulatory elements associated with the expression of cell identity genes and master transcriptional regulators 13 . Super-enhancer identification (see Methods) performed on our H3K27ac ChIP-seq data suggested the presence of two such elements within the 9q34 region of interest (designated PRRC2B superenhancer and BARHL1/DDX31 super-enhancer, Fig. 3a and Extended Data Fig. 3 ).
GFI1B-activated medulloblastomas with SV breakpoints overlapping the inferred BARHL1/DDX31 super-enhancer (MAGIC_MB360 and ICGC_MB9) showed markedly higher levels of H3K27ac and H3K9ac within this region (compared to non-GFI1B-activated samples), indicative of a potential feedback mechanism that increases the local enhancer signal (Fig. 3a) . Moreover, H3K27ac and H3K9ac both mark the GFI1B locus in these two cases, suggesting 'spreading' of the activating enhancer marks from within the predicted super-enhancer to GFI1B consequent to genomic rearrangement (Fig. 3a) . Allelic analysis of RNAseq and enhancer ChIP-seq data for ICGC_MB9 demonstrated that both GFI1B expression and the active enhancer signals spanning GFI1B originate from the same allele (Fig. 3b) 
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analysis of the same cases revealed profound DNA hypomethylation overlapping the putative enhancers identified by ChIP-seq, further supporting the accessibility of this chromatin to the transcriptional machinery in group 3 medulloblastomas (Fig. 3a) .
To assess directly the capacity of identified enhancer elements to potentiate gene expression, a series of genomic fragments (,2 kb each) tiling two of the constituent enhancers (Fig. 3a , shaded regions) that contribute to the BARHL1/DDX31 super-enhancer were independently tested for enhancer activity. Assays performed in the D425 group 3 medulloblastoma cell line confirmed robust reporter activity for constructs derived from either region, whereas constructs mapping outside of these peak regions failed to yield any detectable signal (Fig. 3c ).
Mutually exclusive GFI1 and GFI1B activation
GFI1B is a paralogue of growth factor independence 1 (GFI1), with both genes functioning as SNAG-domain-containing zinc-finger transcriptional repressors essential for a variety of developmental processes, most notably haematopoiesis [14] [15] [16] . Importantly, extensive mouse genetics and insertional mutagenesis screens have established Gfi1 and Gfi1b as potent proto-oncogenes in subtypes of leukaemias and lymphomas 17, 18 . However, no recurrent somatic SVs affecting GFI1 or GFI1B have been reported in these or any other cancers. Transcriptional analysis showed clear activation of GFI1 in a subset of medulloblastomas (29 of 724, 4.0%), with expression tightly restricted to group 3 medulloblastomas (P , 2 3 10 216 ; Fig. 4a ). Comparison of GFI1 and GFI1B expression 
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among group 3 and group 4 medulloblastomas showed a mutually exclusive pattern of activation (P 5 7.864 3 10
215
; Fig. 4b ), further supportive of their oncogenic roles in medulloblastoma. Collectively, GFI1 and GFI1B expression was observed in 25% and 5% of group 3 and group 4 medulloblastomas, respectively (Extended Data Fig. 4 ). These findings were validated in an independent series of medulloblastomas (n 5 156) by immunohistochemical analysis, confirming mutually exclusive GFI1 and GFI1B expression that contributed to 41% and 10% of group 3 and group 4 cases analysed, respectively (Extended Data  Fig. 4) .
GFI1/GFI1B-expressing medulloblastomas did not form their own discrete subtype within the group 3 subgroup as evaluated by clustering of either gene expression or DNA methylation data (Extended Data  Fig. 5 ). Activation status of GFI1 and GFI1B was associated with patient age in group 3, occurring exclusively in non-infant cases in the gene expression cohort (P , 0.0001, chi-squared test; Extended Data Fig. 5 ). However, no association with patient outcome or other clinical/demographic variables was observed in either our combined gene expression or formalinfixed paraffin-embedded cohorts (Extended Data Fig. 5 ).
To investigate whether GFI1 activation in medulloblastoma is attributable to SV mechanisms similar to those targeting GFI1B, we examined the GFI1 locus in our discovery WGS series of group 3 and group 4 medulloblastomas (n 5 137) and sequenced an additional validation set consisting of 11 non-overlapping GFI1-activated cases. This strategy revealed a diversity of SVs affecting the GFI1 locus or surrounding genomic regions, including interchromosomal translocations (n 5 6), tandem duplications (n 5 4) and a complex rearrangement (n 5 1), respectively, in medulloblastomas exhibiting GFI1 expression (Fig. 4d , e and Extended Data Fig. 6 ). We confirmed somatic SVs in 11 of 14 GFI1-activated cases analysed (Fig. 4c) , demonstrating that, similar to GFI1B, GFI1 activation is typically associated with an underlying SV.
RNA-seq analysis did not disclose evidence for possible GFI1 fusion genes (data not shown), suggesting that the detected rearrangements contribute to GFI1 activation by alternative mechanisms. Observed translocation partners showed no apparent preference for intragenic or intergenic breakpoints (Supplementary Table 2 ). Overlaying histone ChIP-seq data with translocation breakpoint regions revealed activating enhancer-histone modification states close to the observed breakpoints ( Fig. 4e and Extended Data Fig. 7 ), suggesting translocations of the normally repressed GFI1 locus into actively transcribed regions as the likely mechanism of gene activation. Importantly, most GFI1 translocation partners were confirmed to harbour clusters of highly active enhancers consistent with super-enhancers that were situated proximal to sequenced breakpoints, analogous to what we observed for GFI1B-activated cases (Fig. 4e and Extended Data Fig. 7) .
Despite identifying multiple distinct t(1:6) and t(1:9) translocations (Fig. 4d) , the only recurrent SV detected in GFI1-activated medulloblastomas was a focal (,6 kb) tandem duplication located ,45 kb downstream of GFI1, identified in three GFI1-activated samples but not in any other sequenced sample (Extended Data Figs 6 and 7) . Enhancer mark ChIP-seq analysis confirmed that this focal region was profoundly marked by the active H3K27ac mark in the context of tandem duplication but not in non-activated group 3 medulloblastomas (Extended Data  Fig. 7) , suggesting that this region downstream of GFI1 can, when duplicated, promote its activation.
GFI1 and GFI1B promote medulloblastoma formation in vivo
Mouse models of medulloblastoma have given important insights into disease biology 19, 20 . Recently, two group 3 models have been described 21, 22 . Each of these involves overexpression of Myc with Trp53 loss-offunction-a combination not typically observed in human medulloblastomas, as MYC amplification/overexpression (group 3) and TP53 mutations (WNT and SHH subgroups) occur in different subgroups 5, 23 . Group 3 medulloblastoma expression data confirmed significant upregulation of MYC in GFI1-activated cases versus non-GFI1/GFI1B-activated, subgroup-matched counterparts (Extended Data Fig. 8 ). Pathway analysis identified MYC target gene sets as being highly enriched in GFI1/GFI1B-activated group 3 medulloblastomas (Extended Data  Fig. 8 ). Additionally, co-occurrence of MYC amplification and GFI1 activation was noted in a subset of group 3 medulloblastomas (Extended Data Fig. 8 ), further suggesting that GFI1 and MYC may cooperate to promote group 3 medulloblastoma. Indeed, Gfi1 and Myc are known to function as synergistic oncogenes and enhance T-cell lymphomagenesis in transgenic mouse models 24, 25 . To evaluate whether GFI1 and GFI1B can function as novel medulloblastoma oncogenes, we used an orthotopic transplantation model 21 whereby retroviruses encoding GFI1 or GFI1B were transduced either alone or in combination with viruses encoding MYC into neural stem cells, followed by their transplantation into the cerebella of immunocompromised mice (Fig. 5a ). Neither GFI1 nor GFI1B alone was sufficient to promote 
Myc (n = 8) , MYC 1 GFI1, and MYC 1 GFI1B models based on cross-species molecular classification.
RESEARCH ARTICLE
tumorigenesis in this system (Fig. 5c and Extended Data Fig. 9 ). When combined with MYC, however (which is also insufficient to generate medulloblastoma on its own in this system 21 ), both GFI1 (that is, MYC 1 GFI1) and GFI1B (that is Fig. 5b-f) .
Cerebellar sections derived from either MYC 1 GFI1 or MYC 1 GFI1B recipient mice showed large masses of infiltrating tumour cells with marked cellular pleomorphism, morphologically consistent with large cell, anaplastic (LCA) medulloblastoma (Fig. 5e and Extended Data Fig. 9 ). LCA histology is significantly more prevalent in group 3 medulloblastoma (,20-25% of cases) than in other medulloblastoma subgroups 6, 7 . Metastatic dissemination was also noted in 30-50% of MYC 1 GFI1 and MYC 1 GFI1B tumour-bearing mice (Fig. 5d and data not shown), paralleling the high frequency of metastasis seen in group 3 medulloblastoma patients 6, 7 . Moreover, immunofluorescence microscopy confirmed that MYC 1 GFI1 and MYC 1 GFI1B tumours are highly proliferative and express neuronal but not glial lineage markers ( Fig. 5f and Extended Data Fig. 9 ), consistent with a medulloblastomalike immunophenotype. Transcriptional profiling and subsequent multidimensional scaling analysis demonstrated a notable similarity between the GFI1-and GFI1B-driven models and confirmed an expression signature consistent with human group 3 medulloblastoma counterparts, suggesting that these models recapitulate molecular characteristics of the human disease ( Fig. 5g and Extended Data Fig. 9 ).
Discussion
Medulloblastoma sequencing studies have highlighted the intertumoral molecular heterogeneity underpinning this malignancy, revealing very few recurrently mutated driver genes, especially in group 3 and group 4 (ref. 5). Here, we have identified somatic genomic rearrangements in association with mutually exclusive GFI1 and GFI1B activation in approximately one-third of group 3 medulloblastomas-now qualifying these oncogenes as the most prevalent drivers in this subgroup (Fig. 6) . Moreover, 5-10% of group 4 medulloblastomas harbour analogous SV associated with GFI1/GFI1B activation, reinforcing the notion that these subgroups share some biological similarities 6, 7 . The verification of diverse SVs in nearly all GFI1/GFI1B-activated medulloblastomas analysed in this study has implications for future cancer genome studies. Conventional approaches for identifying genes recurrently targeted by SV in cancer usually focus on minimal common regions of aberration and require that putative gene targets are (at least partially) included within these altered regions 9 . In contrast to the high-level amplifications known to target MYC, MYCN and other recognized medulloblastoma oncogenes 3, 8 , GFI1 and GFI1B are not amplified in medulloblastoma. Observations extracted from the current study revealed that (1) a considerable proportion of SVs leading to GFI1 and GFI1B activation do not actually include the target gene itself; and (2) multiple distinct classes of SV including duplication, deletion, inversion and other complex rearrangements can converge on activation of a single target, often without associated gene-level copy-number change. Our findings suggest that similar mechanisms leading to gene deregulation (that is, activation of oncogenic drivers) might have thus far been overlooked in other cancers.
SV-dependent redistribution of GFI1 and GFI1B from regions of transcriptionally silent chromatin to regions populated with active enhancers, such as super-enhancers (Fig. 6) , underscores the diversity of interplay between the cancer genome and epigenome [26] [27] [28] . Activation of GFI1 and GFI1B seemingly does not rely on specific epigenetic deregulation but rather implicates a form of 'enhancer hijacking' whereby oncogene activation hinges on the appropriation of a physiologically active epigenetic state from proximal or distant loci, including those mapping to other chromosomes. This concept of merging oncogenes with active regulatory elements has long been observed in lymphoid malignancies, where translocations are known to relocate MYC, BCL2 and other oncogenes adjacent to highly active promoter or enhancer loci, most commonly those belonging to the immunoglobulin genes (that is, IgH/IgL loci) or T-cell receptors (that is, TCR-a/b loci) 29 . To the best of our knowledge, this is the first report to substantiate such a phenomenon in brain tumours.
We have discovered a series of highly variable genomic rearrangements leading to oncogene activation in a significant proportion of cases from poorly understood medulloblastoma subgroups, implicating GFI1 and GFI1B as novel oncogenic drivers worthy of pursuit as candidates for molecularly targeted therapy. The patterns of rearrangement associated with GFI1 and GFI1B activation described here have broad-reaching implications for cancer genomics, and warrant the implementation of similar efforts to revisit existing sequencing data using analytical approaches that extend beyond the coding genome. On the basis of our observations, it is tempting to speculate that similar 'enhancer hijacking' may be equally prevalent in other solid cancers.
METHODS SUMMARY
All patient material included in this study was collected after receiving informed consent from the patients and their families. Medulloblastoma samples were collected at first resection, before adjuvant chemotherapy or radiotherapy. Full details on the sequencing cohorts included in this report are summarized in Supplementary Table 1 . Medulloblastoma subgroups were assigned using gene expression array data, a custom nanoString CodeSet, DNA methylation profiling, or a combination of the above, as previously described 7, 30, 31 . WGS and long-range paired-end mapping were performed as described 2, 3 . WGBS and DNA methylation analysis was conducted as described 32 . Chromatin extraction, immunoprecipitation and library preparation for ChIP-seq studies was performed using proprietary methods at Active Motif (Carlsbad). H3K27ac and H3K9ac peaks were called using underlying GFI1 and GFI1B activation in medulloblastoma. Predominant mechanisms of SV and corresponding genomic redistribution of active enhancers, including super-enhancers, observed in GFI1/GFI1B-activated medulloblastomas. Activation of GFI1 and GFI1B occurs in a mutually exclusive manner in either group 3 or group 4 and both oncogenes can cooperate with MYC to promote medulloblastoma pathogenesis. . Super-enhancers were inferred using the ROSE algorithm with default parameters as described 28 . Affymetrix expression array profiling of human and mouse tumour RNAs was performed at core facilities within the Amsterdam Medical Centre (Amsterdam, Netherlands), German Cancer Research Center (Heidelberg, Germany), and The Hospital for Sick Children (Toronto, Canada). Mouse studies were conducted at the Sanford-Burnham Medical Research Institute and Sanford Consortium for Regenerative Medicine Animal Facilities in accordance with national regulations using procedures approved by the Institutional Animal Care and Use Committees at Sanford-Burnham and the University of California San Diego.
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Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
General statistical methods. All statistical tests were performed in the R Statistical Environment (R version 3.0.0) unless otherwise specified. The KolmogorovSmirnov test was used to compare candidate gene expression in chr9q34 SV cases to non-SV cases. Differential expression of GFI1 and GFI1B across medulloblastoma subgroups was calculated using ANOVA. Enrichment of underlying locusspecific SVs in GFI1/GFI1B-expressing cases was calculated using Fisher's exact test. Mutual exclusivity of GFI1 and GFI1B expression in group 3 and group 4 medulloblastomas was determined using Fisher's exact test. Survival analyses were performed in GraphPad Prism 5 using the log-rank (Mantel-Cox) test to compare survival differences between groups. Sample collection and preparation. An Institutional Review Board ethical vote (Ethics Committee of the Medical Faculty of Heidelberg) was obtained according to ICGC guidelines (http://www.icgc.org), along with informed consent for all participants. No patient underwent chemotherapy or radiotherapy before surgical removal of the primary tumour. Tumour tissues were subjected to neuropathological review for confirmation of histology and for tumour cell content .80%. Analytes were isolated as previously described 2 . Cells were cultured at 37 uC with 5% CO 2 . D425_Med MB cells (D425; a gift from Professor Darrell D. Bigner) were cultured in DMEM with 10% FCS (Life Technologies) and regularly authenticated and tested for mycoplasma (Multiplexion, Heidelberg, Germany). Validation samples for WGS were obtained in accordance with the Research Ethics Board at The Hospital for Sick Children (Toronto, Canada). High-throughput sequencing data generation. Short-insert paired-end sequencing. Samples were processed and libraries sequenced as previously described 2 . Medulloblastoma and germline WGS data 4 generated by the Paediatric Cancer Genome Project (http://explore.pediatriccancergenomeproject.org/) was accessed from The European Genome-phenome Archive (Study ID EGAS00001000347). The original alignments of this WGS data were performed against either reference genome hg18 or hg19. For comparability with our data, the alignment files in hg18 have been converted to FASTQ files using Picard tools (http://picard.sourceforge. net) providing the 'SamToFastq' option. For the alignment of the FASTQ files, the same reference genome as used in the creation of the original hg19 BAM files has been used along with BWA for alignment and Picard for merging and duplicate read filtering. Long-range paired-end sequencing data generation. Long-range (or 'Mate-pair') DNA library preparation was carried out as previously described 2 or using the newer Nextera Mate Pair Sample Preparation Kit (Illumina). In brief, 4 mg of high-molecularmass genomic DNA were fragmented by the Tagmentation reaction in 400 ml, followed by the strand displacement and AMPure XP (Agencourt) clean-up reaction. Samples were size selected to 4-6 kb with a gel step following the Gel-Plus path of the protocol. 300-550 ng of size-selected DNA were circularized in 400 ml for 16 h at 30 uC. The library was then constructed after an exonuclease digestion step to get rid of remaining linear DNA, fragmentation to 300-700 bp with a Covaris S2 instrument (LGC Genomics), binding to streptavidin beads and Illumina Truseq adaptor ligation. Final library was obtained after PCR for 1 min at 98 uC, followed by 9 cycles of 30 s at 98 uC, 30 s at 60 uC, 1 min at 72 uC and a final 5 min at 72 uC step. Deep sequencing was carried out with the Illumina HiSeq2000 (2 3 101 bp) instrument to reach an average physical coverage of 20-303. ChIP sequencing. Chromatin extraction, immunoprecipitation and library preparation for ChIP-seq were performed at Active Motif (Carlsbad, CA) according to proprietary methods. Briefly, 15 mg of chromatin were used as input for ChIP with ChIP-grade antibodies recognizing H3K27ac (AM#39133, Active Motif), H3K9ac (AM#39918, Active Motif), or H3K27me3 (#07-449, Millipore). Libraries were sequenced on the Illumina HiSeq 2000 platform using 2 3 101 cycles according to the manufacturer's instructions. Whole-genome bisulphite sequencing. Whole-genome bisulphite library preparation was carried out as recently described 34 , with modifications to a previously published protocol 35 . In brief, 5 mg of genomic DNA were sheared using a Covaris device (Covaris Inc.). After adaptor ligation, DNA fragments with insert lengths of 200-250 bp were isolated using an E-Gel electrophoresis system (Life Technologies) and bisulphite converted using the EZ DNA Methylation kit (Zymo Research). PCR amplification of the fragments was performed in six parallel reactions per sample using the FastStart High Fidelity PCR kit (Roche). Library aliquots were then pooled per sample and sequenced on an Illumina HiSeq 2000 machine. RNA sequencing. RNA quality control was performed using the 2100 Bioanalyzer platform (Agilent). RNA sequencing libraries were prepared using the TruSeq stranded protocol with Ribo-Zero Gold (Illumina) and sequenced on the Illumina HiSeq 2000 platform with 2 3 51 cycles according to the manufacturer's instructions. High-throughput sequencing data analysis. Whole-genome sequencing. Shortinsert WGS data was analysed as previously described 2 . Long-range paired-end sequencing reads were aligned to the hg19 assembly of the human reference genome using the Illumina-provided alignment software (ELAND, version 2).
Structural variant discovery and filtering. Deletions, tandem duplications, inversion, translocations, as well as complex rearrangements resulting in the corresponding paired-end signatures were inferred using DELLY v0.0.11 (ref. 36) . We considered all those predictions as somatic that were not present in a set of 1,000 Genomes Project (1000GP; http://1000genomes.org) 37 samples corresponding to germline samples taken from normal healthy individuals. Specifically, we used DELLY to infer variants in 1,106 healthy samples belonging to phase 1 of the 1000GP. Furthermore, we inferred variants in the germline samples belonging to the studied tumours. For a given tumour sample, we considered all those variants as somatic that were present neither in any of the 1000GP samples nor in any of the additional germline samples. Two SVs were considered as identical if their start and end coordinates differed by less than 5.0 kb (approximate insert size of a long-range pairedend library) and if their reciprocal overlap was larger than 50%. Variants that were present in the control samples were either true germline variants or represented artefacts caused by misalignment of reads (for example, due to inaccuracies within the human reference genome). To consider a variant prediction as high-confidence we further required at least four supporting read pairs with a minimum median mapping quality of 20 for each event to exclude false-positive predictions caused by randomly mapping low-quality reads. Region identification. We divided the human reference genome into overlapping 1-Mb windows (100-kb offset). For each window, we counted the number of samples with at least one SV breakpoint in the given region (based on short-insert as well as long-insert paired-end sequencing data). Only focal high-confidence SV predictions were used in this analysis (20 kb to 10 Mb in size). Windows affected in at least five samples were investigated manually. Copy-number analysis. We determined the number of sequencing reads per nonoverlapping genomic window of size 250 bp (high-coverage paired-end data) or 1,000 bp (low-coverage long-range paired-end data) for tumour samples with chr9q34 or chr1p22 SV and their corresponding controls. Tumour values were normalized by the ratio of read counts between tumour and controls within a 500-kb region. Subsequently, for each window, the log 2 ratio between normalized tumour and control counts was determined. These values were averaged along a sliding window of 5 kb (short-insert paired-end data) or 10 kb (long-range paired-end data). For tumour samples without a matching control sample, the control of ICGC_ MB230 was used. ChIP sequencing. Histone ChIP-seq data for H3K27ac, H3K9ac and H3K27me3 was processed by the Illumina analysis pipeline (version 1.8.3) and aligned to the Human Reference Genome (assembly hg19, GRCh37) using BWA version 0.5.9-r16 (ref. 38) . Putative PCR duplicates were filtered using Picard MarkDuplicates (http://picard.sourceforge.net). For downstream analyses, we generated wholegenome coverage tracks with reads normalized to all properly paired reads (RPM, paired-end reads/fragments per million). We used igvtools version 2.2.2 (http:// www.broadinstitute.org/igv/igvtools) and the non-default parameter-pairs and a window size of 25. For peak-calling of histone marks, ChIP-seq data for each histone modification (H3K27ac or H3K9ac) was used to generate individual BED files for analysed samples using BEDTools 39 . Individual BED files were then combined for each histone modification and peaks were called using the Bioconductor BayesPeak package in R 33 . Super-enhancers were identified using the ROSE algorithm with default parameters (stitching distance of 12,500 bp and promoter exclusion region of 62,000 bp around TSS) 28 . Briefly, peaks called via BayesPeak were used as constituent enhancers to run the algorithm and super-enhancers were called by ranking of H3K27ac signal at stitched constituent enhancers. Whole-genome bisulphite sequencing. WGBS sequencing data was analysed using methylCtools (Hovestadt et al., manuscript in preparation). In brief, methylCtools builds on BWA and adds functionality for aligning bisulphite treated DNA to a reference genome in a similar manner as described previously 40 . Sequencing reads were adaptor-trimmed using SeqPrep (https://github.com/jstjohn/SeqPrep) and translated to a fully C-to-T converted state. Alignments were performed against a single index of both in silico bisulphite-converted strands of the human reference genome (hg19, NCBI build 37.1) using BWA version 0.6.1-r104 (ref. 38 ) and the non-default parameters -q 20 -s. Previously translated bases were translated back to their original state, and reads mapping antisense to the respective reference strand were removed. Putative PCR duplicates were filtered using Picard MarkDuplicates (http://picard.sourceforge.net). Non-conversion rates were estimated on the basis of lambda phage genome spike-ins. Single base pair methylation ratios (beta-values) were determined by quantifying evidence for methylated (unconverted) and unmethylated (converted) cytosines at all CpG positions. Only properly paired or singleton reads with mapping quality of $1 and bases with Phred-scaled quality score of $20 were considered. To account for population variability, we filtered CpGs for which more than 25% of reads at a given position (on either strand) were not supportive of this CpG being in fact a CpG in the sample being analysed. Subsequently, information from both strands was combined and CpGs with coverage less than five reads were set as NA.
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RNA sequencing. Demultiplexed FASTQ files were generated using the Bcl2FastQ conversion software (Illumina, version 1.8.4). The resulting sequencing reads were aligned to the human genome reference build hg19 (version human_g1k_v37 -1,000 Genomes Project Phase 1) using BWA version 0.5.9-r16 (ref. 38 ) with default parameters. Only the chromosomes 1-22, X, Y and M were used for the mapping. Read coverage plots were prepared using the UCSC Genome Browser showing the number of aligned reads for each genomic position per million mapped reads (RPM) with mapping quality MAPQ .1. The sequencing reads were also used as input for the TopHat2-Fusion algorithm 41 for detection of gene fusion breakpoints. Allelic analysis. Germline SNPs were determined using Samtools and BCFtools. For each SNP, the number of reads in the tumour DNA-, RNA-, and ChIP-seq data supporting the alternative or the reference allele were counted using Samtools mpileup. Only bases with phred score .20 were considered. Only heterozygous SNPs covered by at least 4 sequencing reads in each data set were included in the final summary. PCR and Sanger sequencing validation of structural variants. PCR experiments were performed as follows: 10 ng of genomic DNA were used with the SequalPrep Long PCR Kit (Invitrogen) in 20 ml volumes using the following PCR conditions in a MJ Mini thermocycler (BioRad): 94 uC for 3 min, followed by 10 cycles of 94 uC for 10 s, 62 uC for 30 s and 68 uC for 6 min and 25 cycles of 94 uC for 10 s, 60 uC for 30 s and 68 uC for 7 min, followed by a final cycle of 72 uC for 10 min. PCR products were analysed on a 1% agarose gel stained with Sybr Safe Dye (Invitrogen). Gelextracted bands using the NucleoSpin Gel and PCR Clean-up Kit (MachereyNagel) were capillary sequenced at GATC Biotech AG to analyse SV breakpoints. Expression array processing and data analysis. General array processing. For gene expression array profiling of human medulloblastomas and normal cerebellar controls, high-quality RNAs were processed and hybridized to either (i) the Affymetrix Gene 1.1 ST array at The Centre for Applied Genomics (TCAG, Toronto, Canada) or (ii) the Affymetrix U133 Plus2.0 expression array at the Microarray Department of the University of Amsterdam (Amsterdam, the Netherlands). Sample library preparation, hybridization, and quality control were performed according to protocols recommended by the manufacturer. The CEL files were quantile normalized using Expression Console (v1.1.2; Affymetrix, USA) and signal estimates determined using the RMA algorithm.
Mouse medulloblastomas, non-neoplastic cerebellar stem cells (NSCs), and normal mouse cerebella were analysed using the Affymetrix Mouse Genome 430 2.0 expression array according to the manufacturer's instructions at the DKFZ Genomics and Proteomics Core Facility (Heidelberg, Germany). The CEL files were quantile normalized using Expression Console (v1.1.2; Affymetrix, USA) and signal estimates determined using the RMA algorithm. Merging of expression array platforms. Gene expression array data generated using the Affymetrix Gene 1.1 ST array and U133 Plus2.0 array platforms was merged in order to generate a combined series that would facilitate more streamlined downstream analyses. For each platform, a contrast value per gene was calculated by subtracting the mean expression of that gene across all samples hybridized on that platform from each individual sample (see formula below), and the resulting contrast values of the two platforms were then combined.
Contrast geneA in SampleX 5 Gene A expression in Sample X 2 mean (Gene A expression)
This method minimized possible batch effects existing between the two array platforms and allowed for downstream analyses containing the combined series. Identification of GFI1-and GFI1B-activated medulloblastomas. After combining the gene expression data for the two expression array platforms, for both GFI1 and GFI1B, expression values were modelled by fitting two normal distributions to the data using the R package 'mclust' 42 . With a P value cut-off of P , 0.0001, threshold expressions for GFI1 and GFI1B were identified as contrast scores of 0.64 and 0.65, respectively. Samples having expression greater than or equal to the thresholds were called as GFI1-or GFI1B-activated. Pathway analysis. Medulloblastoma expression array profiles (Affymetrix Gene 1.1 ST) were used to fit a linear model for each gene using group 3 status, GFI1 expression, and GFI1B expression as covariates. The R package 'limma' was used to perform these fits. The average rank of the statistical significance of the GFI1 and GFI1B coefficients was used to perform a Mann-Whitney U-test for a given collection of genes (the null hypothesis being that the genes in a gene set are not ranked any higher than those which are not). In cases where multiple probes matched a single gene, the higher-ranking probe was used. The gene sets contained in the c2-c6 collections from the Molecular Signatures Database (MSigDB) were tested 43 . The P values obtained for each gene set in a collection underwent a Benjamini-Hochberg correction to correct for multiple testing. Cross-species comparisons of human and mouse medulloblastomas. Human medulloblastoma samples were analysed on the Affymetrix U133Plus2 platform and normalized by the MAS5 algorithm. Mouse tumours were analysed on the Affymetrix Mouse Genome 430 2.0 platform and similarly normalized by MAS5 using the 'affy' (v1.38) package within the R Statistical Environment (v 3.0.2). Human and mouse expression profiles were matched by homologues using official gene symbols and filtered for genes that exhibit conserved expression across 32 matched human and mouse tissues 44 as determined by Pearson correlation tests with multiple hypotheses correction using the Benjamini-Hochberg false discovery rate method (FDR ,0.1). Mouse adult cerebellum, fetal cerebellum and Ptch1 1/2 medulloblastoma samples were matched against the most similar human adult cerebellum, fetal cerebellum and SHH medulloblastoma samples, respectively, by Pearson correlation of expression profiles. Subsequently, these matched sample pairs were designated as replicate samples for cross-platform calibration by the Linear Cross-Platform Integration of Microarray Data (LTR) algorithm 45 as implemented in the 'LTR' package (v 1.0.0).
Following gene filtering and expression calibration, the human and mouse expression profiles were combined and analysed by multidimensional scaling. The first two dimensions were disregarded, as expression differences between human and mouse dominated them. The third dimension was identified as the medulloblastoma subgroup spectrum, as the coordinate values discriminate samples from different human medulloblastoma subgroups. Using this molecular subgroup spectrum, mouse samples were classified using a Bayesian classifier initialized with a uniform prior. The posterior probabilities were calculated as the normalized product of the prior and the likelihood of Gaussian distribution parameters with mean and variance estimates from each of the human medulloblastoma subgroups. Luciferase enhancer assays. Candidate enhancer regions were amplified by PCR using the primer sets listed below and cloned into the pGL4.24[luc2P/minP] Vector (Promega) containing a multiple cloning region for insertion of a response element of interest upstream of a minimal promoter and the luciferase reporter gene, luc2P. Primer sequences. The following primer sequences were used: BARHL1/DDX31 SE: region 1, forward primer GAAGGTACCATCCCCACTTCCTGGTAAGG, reverse primer GAAGGTACCTTCTTTGGGGAAATCATTGG; BARHL1/DDX31 SE: region 2, forward primer GAAGGTACCCTGAGAGTTTGGGCTTCAGG, reverse primer GAAGGTACCGCCTGCCAATTTTTATGTGG; BARHL1/DDX31 SE: region 3, forward primer GAAGGTACCTGTCTCCAAGTGTGGTTTCG, reverse primer GAAGGTACCTGAGCAGGGGATTTAACAGG; BARHL1/DDX31 SE: region 4, forward primer GAAGGTACCAGGGGTATCGTGGTCTTGG, reverse primer GAAGGTACCGGAAAGCACACGTGAAAAGG; BARHL1/DDX31 SE: region 5, forward primer AAGGTACCAGTGTGTCAACCACCCACAA, reverse primer AAGAGCTCGGATGGAGTGCAGTCACCTT; BARHL1/DDX31 SE: region 6, forward primer AAGGTACCGAAATTCCCCAGGAGGAGAG, reverse primer AAGAGCTCCCAATGCACCCTACGTTTCT; BARHL1/DDX31 SE: region 7, forward primer AAGGTACCCACCCAGCTCTTCTCCAGTC, reverse primer AAGAGCTCCTCCTCCAGCACAACACTGA; BARHL1/DDX31 SE: region 8, forward primer AAGGTACCCTGTAGCCTCGACCTTCTGG, reverse primer AAGAGCTCCCTTCAGAGCACTTGTAGGAGAA.
For evaluation of enhancer activity, D425 group 3 medulloblastoma cells were plated on 6-well plates. At 50% confluence, cells were transfected in triplicate with 2.25 mg of the pGL4.24 reporters carrying the DDX31 DNA fragments plus 0.25 mg of phRL-TK encoding Renilla luciferase. Two days post-transfection, the cells were harvested, followed by measurement of luciferase activities using the Dual-Glo Luciferase Assay System (Promega). As a control, the pGL4.24 empty vector was included for calibration of activity obtained with the experimental constructs. The luminescence of the Firefly Luciferase was normalized to the Renilla Luciferase signal obtained from the phRL-TK vector and data was presented as the mean delta-fold activity (Firefly Luciferase/Renilla Luciferase) of experimental transfectants compared to the pGL4.24 empty vector transfectants. Immunohistochemical and FISH analysis of human medulloblastoma samples. Immunohistochemistry (IHC) and FISH were performed on formalin-fixed paraffin-embedded MB sections as previously described 7 . Monoclonal GFI1 (clone 3G8, Sigma) and polyclonal GFI1B (HPA007012, Sigma) antibodies were used at working dilutions of 1:100 with an incubation time of 1 h @ 32uC using the Ventana protocol cc1. Mouse models. Animals. C57BL/6 mice (males and females) were used as a source of cerebellar stem cells and immunocompromised (NOD-scid IL2Rgamma null , NSG) female mice were used as transplantation hosts. Mice were bred and maintained at the Sanford-Burnham and Sanford Consortium Animal Facilities. Experiments were performed in accordance with national regulations using procedures approved by the Institutional Animal Care and Use Committees at Sanford-Burnham and the University of California San Diego. No a priori calculations related to sample size were performed. No specific randomization or blinding was performed. Isolation of cerebellar stem cells. Cerebellar stem cells were isolated as previously described 46 . Briefly, neonatal (p4-p6) cerebella from wild-type C57BL/6 mice were dissected and enzymatically dissociated into single cell suspension. Cells were RESEARCH ARTICLE subjected to Percoll fractionation (GE Healthcare Life Sciences 17-0891-02) and stained (anti-mouse CD133 PE, eBioscience 12-4301-82) and sorted for the Prominin11 (Prom1 1 ) population (approximately 3-4% of cells). Retroviral constructs. Retroviruses employed in this study included MSCV-cMyc T58A -IRES-GFP 21 , MSCV-c-Myc T58A-IRES-Luc, MSCV-Gfi1-IRES-GFP, MSCV-Gfi1-IRES-Luc, MSCV-Gfi1b-IRES-GFP and MSCV-Gfi1b-IRES-Luc. To create the Gfi1 and Gfi1b viral constructs, cDNAs were PCR-amplified and cloned into MSCV-IRES-GFP and MSCV-IRES-Luc. Gfi1 and Gfi1b were PCR-amplified from pCMV6-Gfi1 (MC208542, OriGene) and pCMV6-Gfi1b (MC201880, OriGene), respectively, and EcoRI and XhoI restriction sites were added to the cDNA ends.
Gfi1 PCR primers: forward primer GAATTCACCATGCCGCGCTCATTCC TGGTC, reverse primer CTCGAGTCATTTGAGTCCATGCTGACTCTC. Gfi1b PCR primers: forward primer GAATTCACCATGCCACGGTCCTTTCTAGTG, reverse primer CTCGAGTCACTTGAGATTGTGTTGACTCTC.
The PCR-amplified products were blunt-end-ligated into pJET1.2 (CloneJET PCR Cloning Kit, Thermo Scientific K1231) and then cut with EcoRI and XhoI. The sticky-ended fragments were then ligated into the EcoRI/XhoI-digested MSCV-IRES-GFP and MSCV-IRES-Luc vectors. Orthotopic transplantation and tumour formation. Before transplantation, cerebellar stem cells (Prom1 1 cells) were infected with retroviruses encoding Myc   T58A and Gfi1-or Gfi1b for 20 h. Next, 1 3 10 5 transduced cells were re-suspended in Neurocult NSC Basal medium (Stem Cell Technologies, cat #05700) with Neurocult NSC Proliferation Supplement (Stem Cell Technologies, cat #05701) and injected into the cerebella of NSG mice (6-8 weeks old) using a stereotactic frame equipped with mouse adaptor (David Kopf Instruments). Animals were monitored weekly and euthanized when they showed signs of medulloblastoma. At time of euthanasia, brains were removed for tumour dissection and dissociation or for embedding and sectioning. Tissue sectioning and staining. Mouse brains were fixed with 4% paraformaldehyde and embedded in either paraffin or OCT. Samples for histological analysis were paraffin-embedded, sectioned and stained with H&E by the Sanford-Burnham Histopathology Core Facility. Samples frozen in OCT were sectioned using a Leica CM3050S cryostat. Cryosections were stained overnight with primary antibodies against proliferation (anti-Ki67, Abcam ab15580) and lineage markers (anti-GFAP, Novus Biologicals NB300-141; anti-b3-Tubulin, Cell Signaling 5568) and stained Extended Data Figure 1 | Recurrent somatic copy-number aberrations target a common region on 9q34. Affymetrix SNP6 copy-number output for 22 primary medulloblastomas from the published 8 MAGIC series exhibiting focal somatic copy-number aberrations within the 9q34 region of interest defined by WGS in the current study. Of the affected samples, medulloblastoma subgroup information was available for 15 of 22 cases: SHH (n 5 1*), group 3 (n 5 11) and group 4 (n 5 3). Close examination of the single non-group 3/group 4 medulloblastoma affected by a focal copy-number event in the region (MAGIC_MB1318, SHH) revealed that this sample exhibits a homozygous deletion (in the context of broad chr9q deletion) specifically overlapping TSC1 and is therefore unlikely to be related to the events which target GFI1B for transcriptional activation. Indicated coordinates are based on the hg18 reference genome (NCBI Build 36.1) that was used in the original MAGIC study.
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